IB Net Payout Yields Model

Tilray: Numbers Keep Getting Worse


  • Tilray reported another quarter of highly disappointing results, yet the stock again rallied initially on the numbers.
  • The Canadian cannabis company missed analyst revenue targets by ~10%.
  • The stock remains far too expensive at over 12x key cannabis and beverage revenues.
  • Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our model portfolio. Learn More »
Tilray (TLRY) jumped on FQ2'22 results that somehow impressed the market. The cannabis L.P. actually reported declining cannabis revenues and a meager EBITDA profit after ignoring certain costs that are starting to recur. My investment thesis remains negative on the Canadian cannabis stock, as the company fails to grow cannabis revenues.

Read the full article on Seeking Alpha. 

Disclosure: No position mentioned. Please review the disclaimer page for more details. 


Popular posts from this blog

Aurora Cannabis: Deal Or No Deal

Celsius: Unaltered Growth Story

Hims & Hers Health: Still Firing On Strong Cylinders